Edition:
India

Revance Therapeutics Inc (RVNC.OQ)

RVNC.OQ on NASDAQ Stock Exchange Global Market

30.50USD
23 Feb 2018
Change (% chg)

$-0.20 (-0.65%)
Prev Close
$30.70
Open
$30.75
Day's High
$30.90
Day's Low
$29.45
Volume
64,618
Avg. Vol
111,809
52-wk High
$37.45
52-wk Low
$18.00

Select another date:

Mon, Jan 8 2018

BRIEF-Revance Therapeutics Inc Announced Interim 8-Week Phase 2A Results For Rt002 In Treating Plantar Fasciitis

* REVANCE THERAPEUTICS INC - ANNOUNCED INTERIM 8-WEEK PHASE 2A RESULTS FOR RT002 IN TREATING PLANTAR FASCIITIS

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

Revance will wait to seek backing for Botox-rival

Revance Therapeutics Inc will wait to seek partnerships with bigger drugmakers until it is closer to regulatory approval for its Botox rival treatment, Chief Executive Dan Browne told Reuters in an interview.

BRIEF-Revance Announces Pricing Of Public Offering Of Common Stock

* REVANCE ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Revance Therapeutics Files For Potential Mixed Shelf Offering ‍​‍​

* REVANCE THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING ‍​‍​ Source text: (http://bit.ly/2nwJNaw) Further company coverage:

BRIEF-Revance Announces Proposed Public Offering Of Common Stock

* REVANCE THERAPEUTICS INC - PROPOSED UNDERWRITTEN PUBLIC OFFERING IN WHICH IT WILL ISSUE AND SELL APPROXIMATELY $175 MILLION OF SHARES OF ITS COMMON STOCK

BRIEF-Revance’s RT002 Meets Primary, Secondary Endpoints In Sakura Phase 3 Trials

* REVANCE’S RT002 MEETS PRIMARY AND ALL SECONDARY ENDPOINTS, ACHIEVES 6-MONTH DURATION IN PIVOTAL SAKURA PHASE 3 TRIALS FOR GLABELLAR LINES

BRIEF-Revance Plans Phase 3 Program For RT002 Injectable To Treat Cervical Dystonia

* REVANCE PLANS PHASE 3 PROGRAM FOR RT002 INJECTABLE TO TREAT CERVICAL DYSTONIA

BRIEF-Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

* Revance announces orphan drug designation of RT002 for the treatment of Cervical Dystonia

BRIEF-Revance Therapeutics reports qtrly net loss per share attributable to common stockholders basic and diluted‍​ $1.01

* Revance Therapeutics Inc - ‍sakura 1 & 2 phase 3 pivotal trials on track to report topline results before year-end 2017​

Select another date: